Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHUK | O15111 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 9/20 | 0.49 |
| ▸ | NFATC1 | O95644 | 6/20 | 0.49 |
| ▸ | GSK3B | P49841 | 4/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.46 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30861100 | 1.00 | CHUK (0.50) | CHUKDYRK1ANFATC1GSK3BPDPK1 | |
| SCHEMBL23166366 | 0.86 | HTR6 (0.45) | CHUKDYRK1ANFATC1GSK3BMAPT | |
| SCHEMBL24196331 | 0.80 | ALDH1A1 (0.44) | CHUKGSK3BMAPTHTTLMNA | |
| SCHEMBL23166408 | 0.79 | HTR6 (0.42) | CHUKGSK3BMAPTHTTLMNA | |
| SCHEMBL23166049 | 0.76 | HTR6 (0.38) | CHUKGSK3BMAPTHTTLMNA | |
| SCHEMBL26696331 | 0.75 | MAPT (0.40) | CHUKDYRK1ANFATC1GSK3BPDPK1 | |
| SCHEMBL1849779 | 0.74 | NPC1 (0.51) | MAPTHTTCDK2LMNAALDH1A1 | |
| SCHEMBL12197684 | 0.74 | ALDH1A1 (0.44) | CHUKMAPTHTTLMNAALDH1A1 | |
| SCHEMBL8568179 | 0.73 | ALDH1A1 (0.53) | CHUKMAPTHTTLMNAPOLB | |
| SCHEMBL2181204 | 0.72 | MET (0.62) | MAPTHTTLMNAPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024073073-A2 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| EP-3568390-B1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) | 2024-03-06 | — | — | EP | disclosed |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-11-07 | — | — | US | disclosed |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230116770-A1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2023-04-13 | — | — | US | disclosed |
| US-11452717-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2022-09-27 | — | — | US | disclosed |
| US-20210161873-A1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2021-06-03 | — | — | US | disclosed |
| EP-3568390-A1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2019-11-20 | — | — | EP | disclosed |
| WO-2018132372-A1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2018-07-19 | — | — | WO | disclosed |
| US-8501769-B2 | Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof | ABBVIE INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20110082170-A1 | THIENOPYRIDYL COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-04-07 | — | — | US | disclosed |
| US-7875627-B2 | e.g.1-(4-Chloro-benzyl)-3-(2-methyl-thieno[2,3-c]pyridin-3-yl)-urea; 2-Methyl-thieno[2,3-c]pyridin-3-yl)-carbamic acid 4-trifluoromethylsulfanyl-benzyl ester; controlling pain, urinary incontinence, bladder overactivity, and inflammatory thermal hyperalgesia in mammals | ABBOTT LABORATORIES (US) | 2011-01-25 | — | — | US | disclosed |
| EP-1824860-A2 | THIENOPYRIDYL COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LABORATORIES (US) | 2007-08-29 | — | — | EP | disclosed |
| US-20060148843-A1 | Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof | ABBVIE INC. | 2006-07-06 | — | — | US | disclosed |
| WO-2006063178-A2 | THIENOPYRIDYL COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LABORATORIES (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148843-A1 | Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof | TRPV1, GPR55, P2RX6 | CHUK 944/4885DYRK1A 2695/4885NFATC1 2679/4885 |
| US-11452717-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | NAMPT, NAPRT, NNT | CHUK 1207/4885DYRK1A 4701/4885NFATC1 1837/4885 |
| US-20210161873-A1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | NAMPT, NAPRT, NNT | CHUK 1207/4885DYRK1A 4701/4885NFATC1 1837/4885 |
| US-20110082170-A1 | THIENOPYRIDYL COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | TRPV1, GPR55, P2RX6 | CHUK 944/4885DYRK1A 2695/4885NFATC1 2679/4885 |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | NAMPT, NAPRT, NNT | CHUK 1207/4885DYRK1A 4701/4885NFATC1 1837/4885 |
| US-20230116770-A1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | NAMPT, NAPRT, NNT | CHUK 1207/4885DYRK1A 4701/4885NFATC1 1837/4885 |
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | LRRK2, MAP3K20, MAP3K5 | CHUK 271/4885DYRK1A 309/4885NFATC1 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.